Resmetirom for MASH: A study on safety and effectiveness
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have at least one metabolic condition, such as type 2 diabetes, obesity, high cholesterol, or high blood pressure
- You have a diagnosis of MASH based on a special liver scan or blood test
- You do not have cirrhosis or severe liver scarring
- You do not have chronic viral hepatitis or other liver diseases
- You have not used resmetirom in the last 6 months
- Your kidney function is not severely reduced
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
This study tests a daily pill, resmetirom, to see if it can reduce fat and scarring in the livers of children and teens with MASH, a type of fatty liver disease. It may help improve liver health and prevent further damage.
This trial tests a drug called resmetirom for people who have both a type of fatty liver disease (MASH) and a type of heart failure (HFpEF). It aims to see if the drug can help both conditions. You may be able to join if you have both conditions and meet certain health criteria.
This study tests whether taking rezdiffra (a liver medication) together with other common diabetes or liver drugs is safe and effective for adults with MASH (fatty liver disease) and moderate-to-severe liver scarring. It may help improve liver health and reduce disease progression.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests a new drug called TGM-312-SC01 to see if it can help people with MASH (a type of fatty liver disease that causes inflammation and damage). It is for adults aged 18 to 70 who are otherwise healthy or have MASH.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.